Skip to main content
SpringerLink
Log in

Behandlung menopausaler Beschwerden

Praktische Aspekte aus der aktuellen NICE-Leitlinie

Treatment of menopausal complaints

Practical aspects from the current NICE guidelines

  • Medizin aktuell
  • Published:
Gynäkologische Endokrinologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. National Institute for Health and Care Excellencein commission with National Collaborating Centre for Women’s and Children’s Health (2015) NICE Clinical Guideline Menopause (NCC-WCH), Version 1.2. http://www.nice.org.uk/guidance/indevelopment/gid-cgwave0639. Zugegriffen: 1. Juni 2015

    Google Scholar 

  2. National Institute of Health and Care Excellence (NICE) (2015) Menopause: diagnosis and management. NICE guidelines [NG23]. https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-1837330217413 (Erstellt: November 2015). Zugegriffen: 12. Dezember 15

    Google Scholar 

  3. Sarri G, Davies M, Guideline Development Group (2015) Diagnosis and management of menopause: summary of NICE guidance. BMJ 351:h5746 (http://www.ncbi.nlm.nih.gov/pubmed/26563259) doi:10.1136/bmj.h5746

    PubMed  Google Scholar 

  4. Lumsden MA, Davies M, Sarri G (2016) Guideline Development Group for Menopause: diagnosis and management (NICE Clinical Guideline No 23). JAMA Intern Med 176(8):1205. doi:10.1001/jamainternmed.2016.2761.

    PubMed  Google Scholar 

  5. STRAW + 10 Collaborative Group, Harlow SD, Gass M, Hall JE et al (2012) Executive summary of the stages of reproductive aging workshop + 10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97(4):1159–1168. doi:10.1210/jc.2011-3362

    Google Scholar 

  6. Ortmann O (2009) Hormontherapie in der Peri- und Postmenopause. Kurzversion der interdisziplinären S3-Leitlinie. Frauenarzt 50:840–851 (Langversion: http://www.dggg.de, Bereich „Leitlinien“, AWMF-Leitlinie Reg.Nr. 015/062)

    Google Scholar 

  7. Baber RJ, Panay N, Fenton A (2016) 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19:109–150 (on behalf of the IMS Writing Group)

    CAS  PubMed  Google Scholar 

  8. Neves-E-Castro M, Birkhauser M, Samsioe G et al (2015) EMAS position statement: The ten point guide to the integral management of menopausal health. Maturitas 81:88–92

    PubMed  Google Scholar 

  9. NAMS (2012) The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 19:257–271

    Google Scholar 

  10. Stuenkel CA, Davis SR, Gompel A et al (2015) Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100:3975–4011

    CAS  PubMed  Google Scholar 

  11. Endocrine Society (2010) Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95(Suppl 1):s51–s566

    Google Scholar 

  12. Mueck AO (2015) Anwendungsempfehlungen zur Hormonsubstitution im Klimakterium und Postmenopause. Frauenarzt 56:657–659 (federführend für 10 Institutionen und Gesellschaften)

    Google Scholar 

  13. WHI Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333

    Google Scholar 

  14. WHI Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701–1712

    Google Scholar 

  15. Manson JE, Kaunitz AM (2016) Menopause management – getting clinical care back on track. N Engl J Med 374:803–806

    PubMed  Google Scholar 

  16. Mueck AO (2016) WHI-Autoren mahnen: Millionen Frauen müssen unnötig leiden! Frauenarzt 57:442–443 (federführend für BVF, DGGEF, Zürcher Kreis)

    Google Scholar 

  17. WHI Investigators (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465–1477

    Google Scholar 

  18. Stuenkel CA, Gass MLS, Manson JE et al (2012) A decade after the Women’s Health Initiative – the experts do agree. Menopause 19:846–847

    PubMed  Google Scholar 

  19. Zürcher Kreis (2013) 10 Jahre Women’s Health Initiative (WHI): Was haben wir gelernt? J Gynäkol Endokrinol 23:6–19

    Google Scholar 

  20. Shapiro S (2003) Risks of estrogen plus progestin therapy: A sensitivity analysis of findings in the Women’s Health Initiative randomized controlled trial. Climacteric 6:302–310

    CAS  PubMed  Google Scholar 

  21. Garbe E, Suissa S (2004) Issues to debate on the Women’s Health Initiative (WHI) study. Hormone replacement therapy and acute coronary outcomes: Methodological issues between randomized and observational studies. Hum Reprod 19:8–13

    CAS  PubMed  Google Scholar 

  22. Renoux C, Dell’Aniello S, Garbe D, Suissa S (2010) Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ 340:c2519. doi:10.1136/bmj.c2519

    PubMed  Google Scholar 

  23. Canonico M, Carcaillon L, Plu-Bureau G et al (2016) Postmenopausal hormone therapy and risk of stroke: Impact of the route of estrogen administration and type of progestogen. Stroke 47:1734–1741

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Mikkola TS, Tuomikoski P, Lyytinen H et al (2015) Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 100:4588–4594

    CAS  PubMed  Google Scholar 

  25. Karim R, Dell RM, Greene DF et al (2011) Hip fracture in postmenopausal women after cessation of hormone therapy: Results from a prospective study in a large health management organization. Menopause 18:1172–1177

    PubMed  PubMed Central  Google Scholar 

  26. Mueck AO, Wallwiener D (2007) Brustkrebsrate und HRT-Verordnungen: Differierende Daten aus USA und Europa. Frauenarzt 48:812–816

    Google Scholar 

  27. Mueck AO, Wallwiener D (2007) Brustkrebsrate und HRT-Verordnungen: Weiterhin kontroverse Diskussionen – Antwort zum Leserbrief. Frauenarzt 48:1034–1038

    Google Scholar 

  28. WHI Investigators (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. JAMA 305:1305–1314

    Google Scholar 

  29. Shapiro S, Farmer RTD, Stevenson JC et al (2013) Does Hormone Replacement Therapy (HRT) cause breast cancer? Part 5: Trends in breast cancer incidence in relation to the use of HRT. J Fam Plann Reprod Health Care 39:1–9. doi:10.1136/jfprhc-2012-100508

    Google Scholar 

  30. Shumaker SA, Legault C, Rapp SR et al (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study. JAMA 289:2651–2662

    CAS  PubMed  Google Scholar 

  31. Mueck AO (2003) WHIMS – Risiko für Demenzen vaskulär verursacht? Geburtshilfe Frauenheilkd 63:685–686

    Google Scholar 

  32. Kanaya AM, Herrington D, Vittinghoff E et al (2003) Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study [HERS. Ann Intern Med 138:1–9

    CAS  PubMed  Google Scholar 

  33. Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes on postmenopausal women: results from the Women’s Health Initiative hormone trial. Diabetologia 47:1175–1187

    CAS  PubMed  Google Scholar 

  34. Bonds DE, Lasser N, Qi L, Brzyski R et al (2006) The effect of conjugated equine oestrogen on diabetes incidence: The Women’s Health Initiative randomised trial. Diabetologia 49:459–468

    CAS  PubMed  Google Scholar 

  35. WHI Investigators (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–1657

    Google Scholar 

  36. Mueck AO (2006) WHI: Estrogene verringern das Brustkrebsrisiko signifikant um über 30. Frauenarzt 47:386–388

    Google Scholar 

  37. Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111

    CAS  PubMed  Google Scholar 

  38. Lyytinen H, Pukkala E, Ylikorkala O (2009) Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 113:65–73

    PubMed  Google Scholar 

  39. Schneider C, Jick SS, Meier CR (2009) Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 12:514–524

    CAS  PubMed  Google Scholar 

  40. Cordina-Duverger E, Truong T, Anger A et al (2013) Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS ONE 8(11):e78016

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Canonico M, Oger E, Plu-Bureau G et al (2007) Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens. Circulation 115:840–845

    CAS  PubMed  Google Scholar 

  42. Canonico M, Fournier A, Carcaillon L et al (2010) Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 30:340–345

    CAS  PubMed  Google Scholar 

  43. Mueck AO (2003) HRT: Hoher, auch präventiver Nutzen bei frühem Beginn. Frauenarzt 44:1293–1294

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Klinik und Forschungszentrum für Frauengesundheit, Department für Frauengesundheit, Universitätsklinikum Tübingen, Calwer Str. 7, 72076, Tübingen, Deutschland

    A. O. Mueck

  2. Beijing Obstetrics & Gynecology Hospital, Capital Medical University, Peking, China

    A. O. Mueck

Authors
  1. A. O. Mueck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. O. Mueck.

Ethics declarations

Interessenkonflikt

A.O. Mueck ist Präsident der Deutschen Menopause Gesellschaft e. V. und sitzt im Beirat internationaler Gesellschaften mit Relevanz für die Menopausetherapie. Er war oder ist im wissenschaftlichen Beirat nahezu aller Firmen, die Präparate für die HRT vertreiben und hat für sie Vorträge gehalten, zum Teil wird und wurde auch seine Forschung finanziell unterstützt. Weitere Verbindlichkeiten (Eigentümerinteressen, Aktienkapital, Geschäftsanteile, Verkaufslizenzen usw.) bestehen nicht.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mueck, A.O. Behandlung menopausaler Beschwerden. Gynäkologische Endokrinologie 14, 284–290 (2016). https://doi.org/10.1007/s10304-016-0094-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-016-0094-y

Search

Navigation